WHAT HAPPENS WHEN 3–4+ MITRAL REGURGITATION IS UNTREATED DURING SURGICAL AORTIC VALVE REPLACEMENT? IMPLICATIONS FOR TRANSCATHETER AORTIC VALVE REPLACEMENT

Eric E. Roselli(Cleveland Clinic), Eugene H. Blackstone(Cleveland Clinic), D. T. Johnson(Memorial Hermann), Monica Isabella(Cleveland Clinic), Benico Barzilai(Cleveland Clinic), Jeevanantham Rajeswaran(Cleveland Clinic Lerner College of Medicine), David Johnson(Trinitas Regional Medical Center)
Journal of the American College of Cardiology
March 1, 2013
10.1016/s0735-1097(13)61960-9
Cited by 0

Related Papers

5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial
|The Lancet|2015|1.8k
Duration of Red-Cell Storage and Complications after Cardiac Surgery
|New England Journal of Medicine|2008|1.4k
Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium
|European Heart Journal|2011|1.2k
Guidelines for Perioperative Care in Cardiac Surgery
|JAMA Surgery|2019|1.2k
Expert Consensus Document on the Treatment of Descending Thoracic Aortic Disease Using Endovascular Stent-Grafts
|The Annals of Thoracic Surgery|2008|855